Core Insights - Evaxion Biotech A/S is actively participating in various investor and scientific conferences in the US and Europe to provide updates and engage with stakeholders, which is a key part of its strategy to identify potential partnerships and collaborations [1][2] Conference Participation - Evaxion's upcoming conference schedule includes: - Immunotherapy and Immuno-Oncology Congress, March 12-14 in London - HC Wainwright AI Based Drug Discovery & Development Conference, April 2 (Virtual) - Jones Healthcare and Technology Innovation Conference, April 8-9 in Las Vegas - World Vaccine Congress, April 21-25 in Washington - AACR Annual Meeting, April 25-30 in Chicago - Sidoti Micro-Cap Conference, May 20-21 (Virtual) - Dark Genome Target Discovery & Development Summit, June 16-18 in Boston - BIO International Convention, June 16-19 in Boston - World Conference on Infectious Diseases, June 18-20 in Stockholm - International Neoantigen Summit, June 24-26 in Amsterdam - Additional conferences for stakeholder engagement where Evaxion will participate but not present [3] Company Overview - Evaxion is a pioneering TechBio company utilizing its AI platform, AI-Immunology™, to develop innovative immunotherapies for cancer, bacterial diseases, and viral infections. The company has a clinical-stage oncology pipeline of personalized vaccines and a preclinical pipeline targeting infectious diseases with significant unmet medical needs [4]

Core Viewpoint - Evaxion Biotech A/S is extending its phase 2 trial of the personalized cancer vaccine EVX-01 from two to three years to enhance the data package and potentially document better treatment effects for advanced melanoma [1][4][9]. Group 1: Trial Details - The trial will allow active participants to enter a one-year extension after completing the initial two-year protocol, receiving additional doses of EVX-01 as monotherapy [2]. - The trial is progressing as planned, with a two-year data readout expected in the second half of 2025, and all active patients have shown a reduction in tumor target lesions [3][9]. - The extension aims to collect more data on clinical response duration and immune activation, which may provide insights into the durability of the immune response [9]. Group 2: Treatment Efficacy - Interim one-year data presented at the ESMO Congress in September 2024 showed a 69% overall response rate, with tumor target lesions reduced in 15 out of 16 patients [7]. - A positive correlation was observed between the AI-Immunology™ platform predictions and immune responses, with 79% of vaccine targets triggering a targeted immune response [7][10]. - In a completed phase 1/2a trial, 67% of metastatic melanoma patients had objective clinical responses, indicating the potential effectiveness of EVX-01 [9][10]. Group 3: Technology and Innovation - EVX-01 is developed using Evaxion's AI-Immunology™ platform, which tailors the vaccine to each patient's unique tumor profile and immune characteristics [5][8]. - The vaccine engages the patient's immune system to mount a targeted response against tumors, representing a novel approach in cancer treatment [5][8].

Core Points - Evaxion Biotech A/S has re-established compliance with Nasdaq's minimum stockholders' equity requirement and will remain listed on the exchange [1][8] - The company has significantly strengthened its equity and cash position, focusing on executing its strategy and pursuing 2025 milestones [2][8] - Evaxion completed a public offering of $10.8 million and raised an additional $7.6 million through other capital market activities, totaling approximately $17 million in cash and equity [5][8] Compliance and Financial Position - On January 28, 2025, Evaxion was given until May 12, 2025, to demonstrate compliance with Nasdaq listing rule 5550(b)(1), which requires stockholders' equity of at least $2.5 million [3] - The company has successfully executed its plan to restore equity and has re-established compliance with Nasdaq [3][4] - Nasdaq has imposed a "Mandatory Panel Monitor" for one year, during which Evaxion must maintain compliance to avoid delisting [4] Future Prospects - Evaxion is in discussions with the European Investment Bank regarding the conversion of €3.5 million of its €7 million loan, which is expected to increase equity by $3.7 million upon completion [6] - The agreement with the EIB is anticipated to be finalized in the first quarter of 2025 [6][8] - The company's cash runway has been extended to mid-2026 due to recent capital market activities [5][8]

Core Viewpoint - Evaxion Biotech A/S has successfully closed a public offering of 3,997,361 American Depositary Shares (ADSs) and warrants, raising gross proceeds of $10.8 million to advance its clinical pipeline and support operational expenses [1][4]. Group 1: Offering Details - The public offering price was set at $2.71 per ADS, with one warrant for every two ADSs purchased [1]. - The warrants have an exercise price of $2.71 per ADS, are immediately exercisable, and will expire five years after issuance [3]. - The offering was facilitated by Lake Street Capital Markets and Jones as exclusive placement agents [4]. Group 2: Participation and Use of Proceeds - MSD Global Health Innovation Fund, along with other healthcare-focused investment funds and members of Evaxion's Board of Directors and Management, participated in the offering [2]. - The net proceeds from the offering will be utilized to advance the company's preclinical and clinical pipeline, as well as for ongoing operating expenses and working capital [4]. Group 3: Company Overview - Evaxion Biotech A/S is a clinical-stage TechBio company that leverages its AI-Immunology™ platform to develop innovative vaccines targeting cancer, bacterial diseases, and viral infections [8]. - The company is focused on creating personalized vaccines and addressing high unmet medical needs in infectious diseases [8].

Core Viewpoint - Evaxion Biotech A/S has announced a public offering of 3,997,361 American Depositary Shares (ADSs) and warrants, priced at $2.71 per ADS, to raise approximately $10.8 million for advancing its clinical pipeline and operational expenses [1][4]. Group 1: Offering Details - The public offering includes warrants to purchase up to 50% of the ADSs offered, with an exercise price of $2.71 per ADS, exercisable immediately and expiring five years after issuance [3]. - The offering is expected to close on or about January 31, 2025, pending customary closing conditions [3]. - Lake Street Capital Markets, LLC and Jones are acting as exclusive placement agents for the offering [4]. Group 2: Participation and Use of Proceeds - MSD Global Health Innovation Fund, along with healthcare-focused investment funds and members of Evaxion's Board of Directors and Management, are participating in the offering [2]. - The net proceeds from the offering will be used to advance the company's preclinical and clinical pipeline, as well as for ongoing operating expenses and working capital [4]. Group 3: Company Overview - Evaxion Biotech A/S is a clinical-stage TechBio company that utilizes its AI-Immunology™ platform to develop vaccines targeting cancer, bacterial diseases, and viral infections [8]. - The company aims to transform patient care by providing innovative and targeted treatment options through its proprietary AI prediction models [8].

Core Points - Evaxion Biotech A/S has received a 180-day extension from Nasdaq to comply with the minimum stockholder's equity requirement, which is now set to May 12, 2025 [1][2] - The company has successfully restored its equity above the $2.5 million minimum through the exercise of prefunded warrants and sales of American Depositary Shares, securing a total of $7.8 million [3][9] - Discussions are ongoing with the European Investment Bank regarding the conversion of €3.5 million of a €7 million loan into equity, which is expected to increase equity by approximately $3.7 million upon completion [4][9] - The CEO of Evaxion expressed confidence in the company's strengthened equity and cash position, as well as ongoing interest in potential partnerships and business development agreements [5][9] Financial Position - Evaxion has restored its equity above the Nasdaq minimum requirement through various financial maneuvers, extending its cash runway until the fourth quarter of 2025 [3][9] - The company has secured additional cash and equity amounting to $7.8 million, which has significantly improved its financial standing [3][9] Compliance Efforts - Following a deficiency letter from Nasdaq in May 2024, Evaxion presented a compliance plan and was granted an initial extension, which expired in November 2024 [7] - After appealing the delisting determination, Evaxion successfully obtained another extension from Nasdaq after a hearing in January 2025 [8]

Core Insights - Evaxion Biotech A/S has completed dosing for all 16 patients in its phase 2 trial of the personalized cancer vaccine EVX-01, which targets advanced melanoma, and is on track for data readout in the second half of 2025 [1][2] - The trial is designed to evaluate EVX-01 in combination with Merck's KEYTRUDA® (pembrolizumab), with each vaccine tailored to the individual patient's tumor profile [5][7] - Interim data from the trial presented at the ESMO Congress in September 2024 showed a 69% overall response rate, with tumor reduction observed in 15 out of 16 patients, indicating strong potential for EVX-01 as a treatment option [6] Company Overview - Evaxion Biotech A/S is a clinical-stage TechBio company that utilizes its AI-Immunology™ platform to develop personalized vaccines for cancer and other diseases [11] - The company aims to transform patient care by providing innovative and targeted treatment options, with a focus on high unmet medical needs in oncology and infectious diseases [11] Product Details - EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancers, specifically designed to engage the patient's immune system [4][7] - The vaccine's development leverages AI technology to create tailored therapies based on individual immune characteristics and tumor profiles [4][7]

Core Viewpoint - Evaxion Biotech A/S has implemented a change in the ratio of its American Depositary Shares (ADSs) to ordinary shares, effective January 14, 2025, transitioning from a one-to-ten ratio to a one-to-fifty ratio, which is akin to a one-for-five reverse ADS split aimed at enhancing liquidity for ADS holders [1][2][5]. Group 1: ADS Ratio Change - The ADS Ratio Change has been made effective, changing from one ADS representing ten ordinary shares to one ADS representing fifty ordinary shares [2]. - This change is designed to support liquidity in the Company's ADSs and is equivalent to a one-for-five reverse ADS split [2][5]. - The exchange of existing ADSs for new ADSs occurred automatically on the effective date, with existing ADSs being cancelled and new ADSs issued [3][4]. Group 2: Impact on Shareholders - All shareholders are uniformly affected by the ADS Ratio Change, which will not alter their percentage interest in the Company's equity, except for fractional ADSs [4]. - Fractional entitlements to new ADSs will be aggregated and sold, with net cash proceeds distributed to ADS holders [4]. - The trading price of the ADS is expected to increase proportionally as a result of the ratio change, although no assurance can be given regarding the actual trading price post-change [5]. Group 3: Company Overview - Evaxion Biotech A/S is a clinical-stage TechBio company that utilizes its AI-Immunology™ platform to develop vaccines targeting cancer, bacterial diseases, and viral infections [6]. - The company is focused on creating innovative and targeted treatment options through its proprietary AI prediction models [6].

COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it is amending the effective date for its plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS ratio”), from the current one (1) ADS representing ten (10) ordinary share to a new ADS ratio of one (1) ADS representing fifty (50) ordinary sha ...

Core Viewpoint - Evaxion Biotech A/S plans to change the ratio of its American Depositary Shares (ADSs) from one ADS representing ten ordinary shares to one ADS representing fifty ordinary shares, effective around January 13, 2025 [1][5]. Company Overview - Evaxion Biotech A/S is a clinical-stage TechBio company that utilizes its AI-Immunology™ platform to develop vaccines targeting cancer, bacterial diseases, and viral infections [6]. - The company focuses on creating personalized vaccines and has a pipeline addressing high unmet medical needs in infectious diseases [6]. ADS Ratio Change Details - The ADS ratio change will automatically exchange every five existing ADSs for one new ADS for holders in the Direct Registration System (DRS) and the Depository Trust Company (DTC) [2][4]. - Registered holders of certificated ADSs must surrender their certificated ADSs to the depositary bank for cancellation to receive the new ADSs [4]. - The change is expected to support liquidity in the company's ADSs, functioning similarly to a one-for-five reverse ADS split [8]. Trading and Market Impact - The trading price of the ADSs is anticipated to increase proportionally due to the ratio change, although no assurance is provided regarding the exact price movement post-change [5]. - No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [9].